搜尋結果
メリスロン錠6mgの添付文書、インタビューフォームなどの情報を掲載しています。エーザイの医療関係者向け情報サイトです。医療用医薬品を適正にご使用いただくための情報を提供しています。
敏使朗是一種含有倍他司汀的產品。 倍他司汀是一種組織胺類似物，對多種組織胺受體有不同的作用。敏使朗適用於治療眩暈和耳鳴。 敏使朗是一種口服藥物，可連同食物一起服用以減少腸胃不適。成人的常用劑量為每日服用三次，每次 6-12mg。
2024年3月29日 · For Print March 29, 2024 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) and muscle relaxant Myonal ® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. (Headquarters ...
2022年11月7日 · For Print November 7, 2022 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal ® (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon ® (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a subsidiary of DKSH ...
販売名 欧文商標名 製造会社 YJコード 薬価 規制区分 メリスロン錠6mg Merislon Tablets エーザイ 1339005F1296 8.7円／錠 処方箋医薬品 注） メリスロン錠12mg Merislon Tablets エーザイ 1339005F2128 10.1円／錠 処方箋医薬品 注）
You can search for reliable information created by pharmaceutical companies. Some of the information is also translated into English. A "drug booklet" is information that describes the medications prescribed by doctors (prescription drugs) in a way that is easy for patients to understand.
2024年3月29日 · Merislon and Myonal have been widely used by patients in Japan for a long time since their launch in 1969 and 1983, respectively. Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products’ disease areas, is the most optimal choice to ensure them to continue contributing to a greater number of patients.
2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon ...
2024年3月29日 · TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon® (generic name: betahistine mesilate) and muscle relaxant Myonal® (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.
3.服用此藥期間如需服用其它藥品時，請主動告訴您的醫師或藥師。. ★★★此藥品可能引起的副作用及處理方式：. 若症狀持續數日或嚴重時，請停藥並立即就醫或與醫師連絡。. 1.可能會有腸胃不適、頭暈、頭痛、疲倦或失眠的症狀，停藥後通常這些症狀便會 ...
